Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Novo Nordisk and GSK plc announced licensing deals with smaller biotechs. The FDA granted approval to Merck's drug, Welireg, ...

Septerna’s stock jumped 69% in premarket trading after the deal was announced. Novo Nordisk’s stock rose 1.2% in European trading.

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO ...

Right now, leading weight-loss drugs must be injected into the body. Pill versions could make the drugs more convenient for patients and easier to ship and store. HealthDay News — Danish ...

Novo Nordisk is banking on fresh leadership ... The company last week announced a licensing deal with the U.S. biotech company Septerna for experimental small-molecule pills for obesity and ...

Novo Nordisk has claimed an edge in the increasingly competitive obesity therapy category after reporting that its Wegovy therapy reduced cardiovascular outcomes by 20% in a phase 3 trial.